Kimberly J. Popovits Sells 5,313 Shares of Genomic Health Inc. (GHDX) Stock
Genomic Health Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 5,313 shares of the company’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $28.88, for a total transaction of $153,439.44. Following the completion of the transaction, the insider now owns 64,933 shares in the company, valued at $1,875,265.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Genomic Health Inc. (NASDAQ:GHDX) opened at 31.67 on Thursday. The firm’s 50 day moving average is $29.55 and its 200 day moving average is $27.77. Genomic Health Inc. has a 52-week low of $22.00 and a 52-week high of $35.79. The stock’s market capitalization is $1.06 billion.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $82.30 million for the quarter, compared to analyst estimates of $83.24 million. Genomic Health had a negative net margin of 5.77% and a negative return on equity of 14.13%. Genomic Health’s revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.36) EPS. Equities analysts expect that Genomic Health Inc. will post ($0.46) earnings per share for the current year.
GHDX has been the topic of several recent research reports. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, October 25th. Canaccord Genuity set a $38.00 target price on shares of Genomic Health and gave the stock a “buy” rating in a report on Wednesday, November 2nd. Jefferies Group increased their target price on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 target price on shares of Genomic Health and gave the stock a “sell” rating in a report on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $32.50.
A number of hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. raised its stake in shares of Genomic Health by 125.6% in the first quarter. Prudential Financial Inc. now owns 42,930 shares of the company’s stock valued at $1,063,000 after buying an additional 23,900 shares during the period. BlackRock Inc. raised its stake in shares of Genomic Health by 1.6% in the first quarter. BlackRock Inc. now owns 46,991 shares of the company’s stock valued at $1,164,000 after buying an additional 719 shares during the period. BlackRock Fund Advisors raised its stake in shares of Genomic Health by 4.3% in the first quarter. BlackRock Fund Advisors now owns 848,433 shares of the company’s stock valued at $21,016,000 after buying an additional 34,729 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Genomic Health by 23.6% in the first quarter. Goldman Sachs Group Inc. now owns 81,866 shares of the company’s stock valued at $2,028,000 after buying an additional 15,635 shares during the period. Finally, Loomis Sayles & Co. L P bought a new stake in shares of Genomic Health during the first quarter valued at about $15,639,000. Hedge funds and other institutional investors own 89.08% of the company’s stock.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.